Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,092 across all filing types
Latest filing 2024-11-08 Proxy Solicitation & In…
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to solicitation of shareholder votes for an annual meeting. It references the definitive proxy statement and additional materials related to the solicitation of proxies. The text emphasizes the importance of reading the definitive proxy statement and proxy card, which are typical components of proxy solicitation materials. The document does not contain financial statements or detailed financial data, nor is it an announcement of earnings or management changes. It is not a report publication announcement since it contains substantive proxy solicitation content. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 3182 characters, which is consistent with a proxy statement or related materials rather than a full annual report or earnings release.
2024-11-08 English
DEFC14A
Proxy Solicitation & Information Statement
2024-11-06 English
Remuneration Information 2024
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the solicitation of proxies for the company's Annual Meeting of Stockholders. It includes detailed information about the proxy contest, board nominees, and shareholder voting instructions. The text explicitly references the filing as a 'Definitive Proxy Statement' and 'Definitive Additional Materials' pursuant to SEC rules. This type of document is classified as 'Remuneration Information' (DEF 14A) because it is a proxy statement that typically includes executive compensation and other governance-related disclosures for shareholder voting purposes. The document is lengthy (15,000 characters) and contains substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is DEF 14A with high confidence.
2024-11-04 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement
2024-11-04 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding the company's preliminary proxy statement (PREC14A). It discusses amendments to the proxy statement, compliance with SEC regulations, and disclosures related to a proxy contest and legal proceedings. The document references the filing of an Amendment No. 1 to the Preliminary Proxy Statement and addresses specific SEC comments on the proxy materials. This type of document is a response to SEC comments on a proxy statement, which is part of the proxy solicitation process. Therefore, it is related to Proxy Solicitation & Information Statement filings. The document is not the proxy statement itself but a correspondence related to it, which still falls under the Proxy Solicitation & Information Statement category as it pertains to the proxy materials and their amendments.
2024-10-30 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a preliminary proxy statement dated October 30, 2024, for AIM ImmunoTech Inc. It invites stockholders to the 2024 Annual Meeting of Stockholders, details the proposals to be voted on (election of directors, ratification of auditor, advisory vote on executive compensation), and urges stockholders to vote using the company's proxy card. The document includes detailed proxy solicitation information, voting instructions, and background on the board nominees. It is not an annual report, earnings release, or other financial report but rather a solicitation of shareholder votes and information related to the annual meeting. This fits the definition of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2024-10-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.